English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, May 9, 2018
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States
Friday, April 20, 2018
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States
Tuesday, April 17, 2018
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy
Wednesday, March 28, 2018
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
Friday, March 2, 2018
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology
Tuesday, October 17, 2017
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China
Friday, September 9, 2016
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8400